Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans


1Molecular Biology and Immunogenetics Laboratory, Instituto Nacional de Enfermedades Respiratorias, Mexico City; 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; 3Cellular Biology Section, Physiology Department, Instituto Nacional de Cardiología, Ignacio Chávez, Mexico City; 4Virgen Macarena Hospital, Seville, Spain.

ABSTRACT
Objective. The aim of this study was to analyze the frequencies of the CCR5 Δ32 deletion and HLA class II alleles in Mexican Amerindian populations and its relevance in the development and severity of RA.

Methods. We studied 212 Mexican Mes-tico subjects (40 patients with refractory RA, 102 patients with non-refractory RA and 70 healthy individuals). At the same time, to evaluate the ethnicity of the CCR5Δ32 deletion we also studied 192 individuals from three Mexican Amerindian populations (70 Mayo (Capomo) individuals, 61 Teenek individuals, and 61 Mazatecan Indians). The Δ32 deletion in the CCR5 structural gene and HLA-DRB1 were determined by a PCR-SSP and a PCR-SSO procedure, respectively.

Results. In the non-refractory RA group the CCR5Δ32 gene frequency was 0.019 and the following genotype frequencies were observed: CCR5/CCR5 = 98.0%, CCR5/CCR5Δ32 = 1.9% and CCR5Δ32/CCR5Δ32 = 1.0%. In the refractory RA group the CCR5Δ32 gene frequency was 0.025 and the genotype distribution was similar to that in the non-refractory RA group. The deletion was not detected in the Mexican Mestizo healthy group, or among the Teenek and Mayo Amerindians, all being individuals homozygous for the wild type allele. In the Mazatecan group the deletion frequency was 1.6% (g.f. = 0.016). We observed a significant increase in the frequency of the DRB1*07 allele in severe RA patients in relation to the non-severe RA group (p = 0.02, OR = 5.65, 95% CI = 0.95-43.05).

Conclusion. Our results suggest that the CCR5Δ32 deletion is not common in Mexican Amerindian populations and this study does not support an important role of CCR5Δ32 in the pathogenesis of RA or a severe form of the disease in Mexicans.

Introduction
In the last six years, the β chemokine receptor gene CCR5 has been an important research topic in human immunodeficiency virus type 1 (HIV-1) infection and acquired immunodeficiency syndrome (AIDS) pathogenesis (1, 2), and its role in the pathophysiology of rheumatic diseases is now being studied. A 32 base pair deletion has been described, which generates a non-functional receptor in the cell surface (CCR5Δ32) (3). Regarding HIV-1 infection and the development of AIDS, several studies sustain that the CCR5-Δ32 deletion carriers show a significant resistance to HIV-1 infection (3, 4). Moreover, some studies have suggested that in HIV infected patients, the deletion correlates with lower levels of circulating viral load, with a slower decline on peripheral CD4+ T cells and, subsequently, with a retarded progression to AIDS (4, 5).

On the other hand, the inability of beta chemokines (RANTES, MIP-1α, MIP-1β) to bind to the non-functional CCR5 causes significant defects in CCR5 and CC chemokine mediated chemotaxis (6). Therefore, the precise role of CCR5 could be relevant in the pathophysiology of inflammatory and immunologic related diseases. Recently, a protective role of CCR5Δ32 in asthma (7), rheumatoid arthritis (8), multiple sclerosis (9), and renal allograft survival (10) has been described. Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the infiltration of lymphocytes, inflammation and destruction of several joints (11). The etiology of RA is unknown but genetic factors play an important role in its pathogenesis (12). Recently, the protective role of the CCR5Δ32 deletion has been described in the Caucasian population (13, 14). Furthermore, this polymorphism has been presumed to be a genetic marker related to the severity of RA (15). The importance of this fact resides in the therapeutic implications for these pathologies. Since it has been postulated that CCR5 and CXC3-expressing cells are determinant in the pathogenesis of inflammatory chronic diseases, the deletion of this CCR5+ cells could be a new strategy for the treatment of RA (16-18).

However, it is important to consider that there is a significant variation in the global distribution of CCR5Δ32 (19), with the highest allele frequency being reported in Ashkenazi Jews (20.93%) (20). In addition, other au-
thors suggest that the ethnic origin of the deletion is markedly related to Caucasian populations (21). Therefore, the geographical distribution of the CCR5 Δ32 allele could help to elucidate the relevance of the deletion in the pathogenesis of RA.

Additionally, MHC class II alleles have been also associated with RA (22). Some HLA alleles encode a conserved amino acid sequence (QKRAA, QRRAA, or RRRAA) at position 70-74 in the third hypervariable region of the DRβ chain “shared epitope” (SE) (23). Several studies, however, have associated the SE HLA-DRB1 alleles with RA severity and progression rather than with susceptibility (24). The aim of this study was to analyze the frequencies of the CCR5Δ32 deletion and HLA class II alleles in Mexican Amerindian populations and its relevance in the development and severity of RA.

Patients and methods

Sample

We studied a sample of 212 Mexican Mestizo subjects (40 patients with refractory RA, 102 patients with non-refractory RA and 70 healthy individuals). The RA patients were diagnosed according to the American College of Rheumatology (ACR) criteria in the Department of Immunology and Rheumatology of the Instituto Nacional de Ciencias Médicas y de la Nutrición Salvador Zubirán. Table I shows demographics, treatment, and disease severity markers in refractory and non-refractory RA patients.

The control group comprised 70 healthy, non-related Mexican Mestizo individuals with no family history of rheumatic diseases. All of them were living in Mexico City and since Mexico City is an important destination for immigration, it can be considered as representative of the rest of the Mexican population. Each individual was asked about his birthplace as well as that of his parents and maternal and paternal grandparents. A Mexican Mestizo is defined as someone born in Mexico who is a descendant of the original autochthonous inhabitants of the region and of individuals, mainly Spaniards, Caucasians and/or blacks, who came to America during the 16th century. We considered Mexican Mestizos only those individuals who were born in Mexico, and both of whose parents were born in Mexico as well.

On the other hand, to evaluate the ethnicity of the CCR5Δ32 deletion, we also studied 192 individuals from three Mexican Amerindian populations. These Amerindian groups included 70 Mayo (Capomo) individuals belonging to the Macro-Yuma linguistic family located in the Northeast of Mexico, 61 Teenek individuals belonging to a linguistically unclassified group located in the Huasteca region of San Luis Potosi State, and 61 Mazatecan Indians who inhabit the north of Oaxaca State. In order to define the genetic background of these three populations, they had been previously characterized by using genetic markers from several chromosomes (blood group, serum haptoglobin, albumin, B factor, HLA, and HSP70-2 genes). Results from these studies have shown that the proportion of Indian, Caucasian, and Negroid genes are 56%, 40%, and 4%, respectively (25-27).

Hla typing

Genomic DNA was isolated from peripheral blood EDTA anticoagulated samples by using standard techniques (28). HLA-DRB1, DRB3, DRB4, DRB5 amplification was done by polymerase chain reaction using Taq DNA polymerase and biotin labeled primers. A PCR-SSO reverse dot blot using the Dynal PCR-SSO Kit (Dynal Biotech Ltd., UK) was performed.

CCR5 genotyping

DNA was amplified by a PCR procedure using 5'-TCAAAAAGAAGGTC TTCATTACACC-3' (sense) and 5'-AGCCCGAGAGAAATAAACAATC-3' (antisense) primers spanning the region of the Δ32 deletion (10). The size of the wild type PCR product was 241 base pairs and the CCR5Δ32 deletion product was 209 base pairs. To confirm the CCR5 polymorphism we employed a previously described PCR-RFLP procedure (1) using the Eco RI restriction endonuclease.

Table I. Main demographic and clinical characteristics in refractory versus non-refractory rheumatoid arthritis patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Refractory RA</th>
<th>Non-refractory RA</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years (mean/SD)</td>
<td>49/15</td>
<td>48/14</td>
<td>0.45</td>
</tr>
<tr>
<td>Formal education in years (mean/SD)</td>
<td>9/4.9</td>
<td>9/5</td>
<td>0.7</td>
</tr>
<tr>
<td>HAQ-Di (mean/SD)</td>
<td>1.4/0.6</td>
<td>0.7/0.5</td>
<td>0.001</td>
</tr>
<tr>
<td>Prednisone (mean/SD)</td>
<td>8.6/5.4</td>
<td>6.2/2.4</td>
<td>0.04</td>
</tr>
<tr>
<td>Erosions (%)</td>
<td>97</td>
<td>24</td>
<td>0.0001</td>
</tr>
<tr>
<td>Rheumatoid factor (%)</td>
<td>85</td>
<td>71</td>
<td>0.08</td>
</tr>
<tr>
<td>Extra-articular manifestations (%)</td>
<td>85</td>
<td>41</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Statistical analysis

Allele and genotype frequencies of CCR5 were obtained by direct counting. The Hardy-Weinberg equilibrium was tested using the ARLEQUIN program. The differences among groups were evaluated by the Mantel-Haenszel, chi-square test that combined the 2 x 2 contingency tables using the EPIINFO statistical program. If the number in any cell was < 5, Fisher’s exact test was used. The p values were corrected by the Bonferroni method multiplying the p value for the number of comparisons. Odds ratios with 95% confidence intervals (OR, 95% CI) were calculated.

Results

The results are shown in Table II. In the non-refractory RA group (N=102) the CCR5Δ32 gene frequency was 0.019 and the following genotype frequencies were observed: CCR5/CCR5 = 97.0%, CCR5/CCR5Δ32 = 1.9% and CCR5Δ32/CCR5Δ32 = 1.0%. In this group the genotype distribution was not in Hardy-Weinberg equilibrium (Chi-square = 6.35, p = 0.01).

The deletion was uncommon in the...
refractory RA group (N= 40) g.f.= 0.025, 95% of refractory RA patients were CCR5/CCR5 homozygous and the last 5% were CCR5/CCR5Δ32 heterozygous. The deletion was not observed in the healthy Mexican Mestizo group nor in the Teenek and Mayo Amerindians, all of whom were individuals homozygous for the wild type allele. In the Mazatecan group the deletion frequency was 1.6%.

HLA-DRB1 typing revealed that the most common alleles were DRB1*04, 07 and 08 in severe RA patients with gene frequencies of 0.350, 0.150 and 0.125, respectively. We observed a significant increase in the frequency of the DRB1*07 allele in severe RA patients in comparison to the non-severe RA group (p=0.02, OR = 5.65, 95% CI = 0.95 - 43.05). We also observed a decreased frequency of the DRB1*13 and *03 alleles in the severe RA group (data not shown).

Discussion

Several studies have implicated the CCR5 β chemokine receptor in the pathogenesis of rheumatoid arthritis (13, 14). In addition, other studies have described the highest frequency of the CCR5Δ32 deletion in Caucasian populations, suggesting its ethnic origin (29). This is the first study done in Mexico to analyze the frequency of the CCR5Δ32 deletion in genetically well defined ethnic groups, including three Amerindian populations, healthy Mestizos, and diseased individuals from different geographical areas of the country (30-32).

The CCR5Δ32 deletion was not found in the Mexican Amerindians nor in the healthy Mexican Mestizo subjects. The absence of this allele was also previously reported in indigenous Brazilian populations (33). Similarly, in our Mexican Mestizo and RA patients, the frequency of the deletion was uncommon, being 1.9% in non-refractory RA patients and 2.5% in the refractory group. Interestingly, the frequency of CCR5Δ32 was not in Hardy-Weinberg equilibrium in the non-severe RA group, suggesting the action of natural selection in the frequency of this gene in this population. Several studies have associated the HLA-DRB1 gene with RA severity and disease progression in several populations, including Mexicans (34, 35).

Moreover, the association with disease severity and the presence of the SE varies among different ethnic groups (36). In this study, we observed an increase in HLA-DRB1*04 allele frequency in the severe RA group (unpublished data), although the statistical analysis did not reveal a significant p value. This fact could be due to the small sample size or the high frequency of the DRB1*04 allele in the general Mexican population (37).

In conclusion, the CCR5Δ32 deletion is not common in Mexican Amerindian populations and confirms the hypothesis of its Caucasian origin. This study does not support an important role of CCR5Δ32 in the pathogenesis of RA and did not show a relationship between the allele and a severe form of the disease in Mexicans.

### References


**Table II.** Allele and genotype frequencies of CCR5-Δ32 deletion in Mexican-Mestizo individuals.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Refractory RA (N=40)</th>
<th>RA* (N=102)</th>
<th>Controls (N=70)</th>
<th>Teenek (N=61)</th>
<th>Capomo (N=61)</th>
<th>Mazatecan (N=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (g.f.)</td>
<td>n (%)</td>
<td>n (g.f.)</td>
<td>n (%)</td>
<td>n (g.f.)</td>
<td>n (%)</td>
</tr>
<tr>
<td>CCR5/CCR5</td>
<td>38 (95.0)</td>
<td>99 (97.0)</td>
<td>70 (100)</td>
<td>61 (100)</td>
<td>70 (100)</td>
<td>59 (96.7)</td>
</tr>
<tr>
<td>CCR5/CCR5Δ32</td>
<td>2 (5.0)</td>
<td>2 (1.9)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (3.2)</td>
</tr>
<tr>
<td>CCR5Δ32/CCR5/Δ32</td>
<td>0 (0)</td>
<td>1 (0.9)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Allele</td>
<td>n (g.f.)</td>
<td>n (g.f.)</td>
<td>n (g.f.)</td>
<td>n (g.f.)</td>
<td>n (g.f.)</td>
<td>n (g.f.)</td>
</tr>
<tr>
<td>CCR5 (wild type)</td>
<td>78 (0.975)</td>
<td>200 (0.980)</td>
<td>140 (1.0)</td>
<td>122 (1.0)</td>
<td>140 (1.0)</td>
<td>120 (0.983)</td>
</tr>
<tr>
<td>CCR5Δ32 (deletion)</td>
<td>2 (0.025)</td>
<td>4 (0.019)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (0.016)</td>
</tr>
</tbody>
</table>

* Hardy-Weinberg equilibrium value in the non-refractory RA group, Chi square = 6.35; p = 0.01.

N = number of patients


16. BRIEF PAPER.

17. BRIEF PAPER.


